Mestag Therapeutics, a Cambridge, MA-based biotech company harnessing new insights into fibroblast-immune interactions, received a £1.5M Grant from Innovate UK’s Cancer Therapeutics Program.
The company intends to use the amount to accelerate the development of its MST-0300 antibody.
Led by CEO Susan Hill, Mestag generates new insights into fibroblast-immune interactions to develop treatments for patients with cancer and inflammatory diseases. It is progressing a pipeline of antibodies designed to direct and drive the immune system using known and emerging fibroblast-immune biology for a distinctly differentiated class of therapeutics.
The pipeline includes a bispecific antibody MST-0300, which leverages a new understanding of tertiary lymphoid structures (TLS) in solid tumors and their role in driving improved patient outcomes, the M402 program, targeting a stromal checkpoint to dampen down the activation of specific immune cell subsets in inflammatory disease, and earlier programs in discovery stage. Separately, in a collaboration with Janssen Biotech, Inc., a Johnson & Johnson company, the company is also identifying novel targets for future therapies.
FinSMEs
28/08/2024